KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Net Cash Flow (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Net Cash Flow readings, the most recent being -$9.5 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 210.8% to -$9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$16.3 million, a 213.34% decrease, with the full-year FY2025 number at -$16.3 million, down 213.34% from a year prior.
  • Net Cash Flow hit -$9.5 million in Q4 2025 for Biocryst Pharmaceuticals, down from -$3.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $303.8 million in Q4 2021 to a low of -$149.5 million in Q1 2023.
  • Median Net Cash Flow over the past 5 years was -$9.0 million (2023), compared with a mean of -$9.2 million.
  • Biggest five-year swings in Net Cash Flow: tumbled 665.62% in 2022 and later surged 304.95% in 2024.
  • Biocryst Pharmaceuticals' Net Cash Flow stood at $303.8 million in 2021, then crashed by 81.05% to $57.6 million in 2022, then crashed by 170.47% to -$40.6 million in 2023, then surged by 121.11% to $8.6 million in 2024, then crashed by 210.8% to -$9.5 million in 2025.
  • The last three reported values for Net Cash Flow were -$9.5 million (Q4 2025), -$3.6 million (Q3 2025), and -$3.3 million (Q2 2025) per Business Quant data.